Skip to content

T · 4594.T · BIOTECHNOLOGY

BrightPath Biotherapeutics Co., Ltd. (4594.T) intrinsic value and stock valuation

$36.00as of 2026-11-21 · Mkt cap 4.99B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

BrightPath Biotherapeutics Co., Ltd. DCF and intrinsic value

InvestorsCraft values 4594.T with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from 4594.T’s statements →

BrightPath Biotherapeutics Co., Ltd. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Tokyo brightpathbio.com

How the business is doing

Fiscal 2014–2026, USD

Revenue
$80K-49.8% 5y CAGRd
20142026
Net income
-$-1.3B
20142026
Free cash flow
-$-1.37B
20142026
Total equity
$2.37B-7.7% 5y CAGRd
20142026

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2014–2026, USD
20262025202420232022
Revenue$80K$1.13M$70K$5.28M$15.4M
Operating income-$-1.3B-$-1.16B-$-1.16B-$-1.47B-$-1.48B
Net income-$-1.3B-$-1.15B-$-1.17B-$-1.49B-$-1.48B
EPSd-$-11.7M-$-14.12M-$-18.21M-$-24.9M-$-28.55M
Operating cash flow-$-1.37B-$-1.25B-$-1.16B-$-1.2B-$-1.51B
Capital expenditure-$-590K-$-1.37M-$-6.19M-$-1.76M-$-17.65M
Free cash flow-$-1.37B-$-1.25B-$-1.16B-$-1.21B-$-1.53B
Total assets$2.6B$1.12B$1.23B$1.7B$2.77B
Total debt$0.00$25M$112.5M$0.00$87.5M
Net debt-$-2.16B-$-785.47M-$-944.86M-$-1.53B-$-2.22B
Total equity$2.37B$925M$979M$1.57B$2.53B
Cash and short-term investments$2.16B$810.5M$1.06B$1.53B$2.31B
Income statement
20262025202420232022
Revenue$80K$1.13M$70K$5.28M$15.4M
Cost of revenue$30K$30K$410K$18.6M$38.4M
Gross profit$60K$1.1M-$-340K-$-13.33M-$-23.03M
Research and development expenses$0.00$888.1M$775.6M$1.17B$1.14B
Selling, general and administrative expenses$1.3B$274M$379.2M$285.3M$317.2M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$1.3B$1.16B$1.15B$1.45B$1.45B
Cost and expenses$1.3B$1.16B$1.16B$1.47B$1.49B
Interest income$20K$70K$10K$20K$30K
Interest expense$0.00$0.00$0.00$60K$360K
Depreciation and amortization$0.00$0.00$400K$16.7M$35.1M
Ebitda-$-1.3B-$-1.16B-$-1.15B-$-1.45B-$-1.44B
Operating income-$-1.3B-$-1.16B-$-1.16B-$-1.47B-$-1.48B
Total other income/expenses, net-$-7.53M$11.7M-$-11.1M-$-16.68M-$-5.74M
Income before tax-$-1.3B-$-1.15B-$-1.17B-$-1.48B-$-1.48B
Income tax expense$2.42M$1.9M$1.9M$1.9M$2.42M
Net income-$-1.3B-$-1.15B-$-1.17B-$-1.49B-$-1.48B
Weighted average shares outstanding$111.6M$81.5M$64.2M$59.7M$52M
Weighted average diluted shares outstanding$111.6M$81.5M$64.2M$59.7M$52M
Balance sheet
20262025202420232022
Cash and short-term investments$2.16B$810.5M$1.06B$1.53B$2.31B
Net receivables$50.9M$64.7M$10K$60K$16.6M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$2.55B$1.07B$1.18B$1.65B$2.7B
Property, plant and equipment, net$0.00$0.00$0.00$0.00$24.9M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$50.6M$49.3M$49.3M$50.2M$75.2M
Total assets$2.6B$1.12B$1.23B$1.7B$2.77B
Accounts payable$30K$40K$20K$80K$1.91M
Short-term debt$0.00$25M$112.5M$0.00$87.5M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$161.4M$131.7M$191M$76.6M$184.7M
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$75.1M$64M$60.3M$57.4M$55.1M
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$236.4M$195.6M$251.3M$133.9M$239.7M
Common stock$2.57B$1.2B$650.7M$362.2M$6.7B
Retained earnings-$-5.11B-$-3.8B-$-2.65B-$-1.49B-$-10.88B
Accumulated other comprehensive income (loss)$20.3M$21.6M$22.8M$20.3M$22.9M
Total equity$2.37B$925M$979M$1.57B$2.53B
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$0.00$25M$112.5M$0.00$87.5M
Net debt-$-2.16B-$-785.47M-$-944.86M-$-1.53B-$-2.22B
Cash flow statement
20262025202420232022
Net income-$-1.3B-$-1.15B-$-1.17B-$-1.48B-$-1.48B
Depreciation and amortization$0.00$0.00$400K$16.7M$35.1M
Stock-based compensation$0.00$0.00$0.00$0.00$0.00
Change in working capital-$-88.45M-$-115.68M$3.51M$16.9M-$-62.88M
Accounts receivable$1.09M-$-1.14M$50K$16.5M-$-16.3M
Inventory$0.00$0.00$0.00-$-238.34M$0.00
Accounts payable-$0.00$10K-$-60K-$-1.83M$1.44M
Net cash provided by operating activities-$-1.37B-$-1.25B-$-1.16B-$-1.2B-$-1.51B
Investments in property, plant and equipment-$-590K-$-1.37M-$-7.65M-$-1.76M-$-17.65M
Acquisitions, net$0.00$0.00$0.00$0.00$80K
Net cash used for investing activities-$-1.93M-$-1.37M-$-7.65M-$-1.76M-$-17.57M
Common stock issued$2.74B$1.09B$573.4M$519.6M$478.1M
Common stock repurchased-$0.00-$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$2.71B$1B$691M$432.1M$569.2M
Net change in cash$1.35B-$-246.89M-$-473.61M-$-774.06M-$-960.36M
Cash at end of period$2.16B$810.5M$1.06B$1.53B$2.31B
Operating cash flow-$-1.37B-$-1.25B-$-1.16B-$-1.2B-$-1.51B
Capital expenditure-$-590K-$-1.37M-$-6.19M-$-1.76M-$-17.65M
Free cash flow-$-1.37B-$-1.25B-$-1.16B-$-1.21B-$-1.53B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About BrightPath Biotherapeutics Co., Ltd.

        BrightPath Biotherapeutics Co., Ltd. develops cancer immunotherapy drugs. The company is developing GRN-1201 that is in Phase II clinical study for the treatment of non-small cell lung cancer, as well as in Phase I clinical study to treat melanoma. It also develops BP1101, a neoantigen vaccine; BP1209, a platform of personalized neoantigen cancer vaccines; and BP1401, an agonist for toll-like receptor 9. In addition, the company offers induced pluripotent stem cell derived regenerated NKT cell therapy for head and neck cancer; and BP2301, an autologous HER2 chimeric antigen receptor-T cell therapy for treating solid tumors sarcoma. Further, it is involved in discovering BP1200, an antibody targeting CD73; BP1210, an immune checkpoint inhibitory antibody; and other antibodies, such as BP1202, BP1206, and BP1211. The company was formerly known as GreenPeptide Co., Ltd. and changed its name to BrightPath Biotherapeutics Co., Ltd. in July 2017. BrightPath Biotherapeutics Co., Ltd. was founded in 2003 and is headquartered in Tokyo, Japan.

        CEO
        Kenichi Nagai
        Employees
        42
        Beta
        1.26

        Explore

        Frequently asked questions

        What is the intrinsic value of BrightPath Biotherapeutics Co., Ltd. (4594.T)?

        InvestorsCraft does not currently publish an intrinsic value for 4594.T. How the IC value is calculated.

        Is 4594.T undervalued?

        InvestorsCraft does not publish an undervaluation signal for 4594.T at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.